BAX - Baxter International Inc.
| Previous Close | 70.71 |
| Open | 70.44 |
| Bid | 68.97 x 1800 |
| Ask | 0.00 x 800 |
| Day's Range | 70.19 - 71.34 |
| 52 Week Range | 60.53 - 76.51 |
| Volume | 2,811,408 |
| Avg. Volume | 2,904,073 |
| Market Cap | 38.066B |
| Beta | 1.06 |
| PE Ratio (TTM) | 43.39 |
| EPS (TTM) | 1.64 |
| Earnings Date | Nov 1, 2018 |
| Forward Dividend & Yield | 0.76 (1.05%) |
| Ex-Dividend Date | 2018-08-30 |
| 1y Target Est | 79.54 |
Markit•3 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
- GlobeNewswire•8 days ago
Recent Analysis Shows Washington Real Estate Investment Trust, FirstEnergy, Alexion Pharmaceuticals, Alaska Air Group, Fortune Brands Home & Security, and Baxter International Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Washington ...
- Reuters•8 days ago
Smiths Group, ICU Medical close to abandoning healthcare merger - Sky News
(Reuters) - British engineering firm Smiths Group Plc (SMIN.L) is close to abandoning talks with U.S.-based ICU Medical Inc (ICUI.O) over a 7 billion pound ($9 billion) merger of their healthcare divisions, ...
- Reuters•8 days ago
Smiths Group, ICU Medical close to abandoning healthcare merger -Sky News
British engineering firm Smiths Group Plc is close to abandoning talks with U.S.-based ICU Medical Inc over a 7 billion pound ($9 billion) merger of their healthcare divisions, Sky News reported on Monday. Smiths is leaning toward a decision to halt negotiations with ICU Medical about the tie-up, more than two months after they got under way, Sky News said. A final decision has yet to be made by Smiths and any change in its position would be announced immediately to the London Stock Exchange, Sky News reported, citing a person close to the British company.
Market Realist•9 days agoAn Overview of TransEnterix’s Q2 2018 Results
TransEnterix (TRXC) reported its second-quarter earnings on Tuesday, August 7, before the market opened. TransEnterix generated second-quarter revenues of $6.4 million compared to $1.6 million in the second quarter of 2017.
Market Realist•13 days agoCan Boston Scientific Maintain Its Strong Sales Momentum?
On July 25, Boston Scientific (BSX) released its Q2 2018 earnings results. It reported revenue of $2.49 billion, exceeding Wall Street’s estimate of ~$2.46 billion and coming in at the higher end of the company’s $2.45 billion–$2.5 billion guidance.
- Market Realist•14 days ago
How Did Zimmer Biomet’s Products Perform in the Second Quarter?
In the second quarter of 2018, Zimmer Biomet’s (ZBH) Knees segment generated revenues $703.0 million, reflecting ~3.4% year-over-year growth. In Q2 2018, in the Americas, EMEA (Europe, Middle East, and Africa), and Asia-Pacific regions, Zimmer Biomet’s Knees segment generated revenues of $408.0 million, $171.0 million, and $124.0 million, respectively, reflecting ~0.7%, ~7.0%, and ~8.1% YoY growth. In the first half of 2018, Zimmer Biomet’s Knees segment generated revenues of $1.4 billion, reflecting ~2.6% YoY growth.
Market Realist•14 days agoHow Zimmer Biomet Fared in the Second Quarter
In the second quarter, Zimmer Biomet (ZBH) generated revenues of $2.0 billion compared to $1.9 billion in the second quarter of 2017, a ~3% YoY increase. In the first half of 2018, Zimmer Biomet reported net revenues of $4.0 billion compared to $3.9 billion in the first half of 2017.
Markit•14 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
- Business Wire•15 days ago
Baxter Announces CE Mark and Regulatory Approval of New Evo IQ Infusion System for the United Kingdom, Ireland, Australia and New Zealand
Baxter International Inc. (BAX), a leader in innovative technology for medication delivery, today announced the CE marking of the Evo IQ Infusion System. In addition to the planned marketing of the device in the United Kingdom, Ireland and New Zealand, the Evo IQ Infusion System recently received regulatory approval by the Therapeutic Goods Administration (TGA) in Australia.
Markit•15 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
- Thomson Reuters StreetEvents•17 days ago
Edited Transcript of BAX earnings conference call or presentation 26-Jul-18 12:30pm GMT
Q2 2018 Baxter International Inc Earnings Call
- Zacks•17 days ago
Abiomed Gets CDSCO Nod for Impella Heart Pumps in India
Abiomed's (ABMD) Impella gets regulatory approval in India; prospects in APAC look upbeat.
- TheStreet.com•20 days ago
The Dip in Baxter International Should Soon Be a Buying Opportunity
Is there more downside risk just ahead or should be look at this weakness as an opportunity to do some buying? In the updated daily bar chart of BAX, below, we can see that prices made a small gap to the downside with heavy volume. The daily On-Balance-Volume (OBV) was steady ahead of this recent dip so we don't have a signal that sellers had become more aggressive in advance of the decline.
Market Realist•20 days agoHow Baxter International Fared in the Second Quarter
Baxter International (BAX) released its Q2 2018 results on July 26. During the quarter, Baxter expanded its medication delivery portfolio with two new infusion pumps. Baxter International’s marketing and administrative expenses increased 8% from $630 million in Q2 2017 to $681 million in Q2 2018, and its research and development expenses increased by 12% from $155 million in Q2 2017 to $174 million in Q2 2018.
Market Realist•20 days agoNovoCure’s Revenues Rose 60% in the Second Quarter
NovoCure (NVCR) released its second-quarter results on July 26. In the second quarter, NovoCure continued to see steady growth in patient prescriptions for new glioblastoma diagnosis. NovoCure reported a net loss of $15.51 million in the second quarter—compared to a net loss of $21.17 million in the second quarter of 2017.
Markit•20 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BAX. Over the last one-month, outflows of investor capital in ETFs holding BAX totaled $440 million.
Zacks•21 days agoBaxter (BAX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
Baxter (BAX) gains on the back of its core Renal Care segment in Q2; solid international sales encourage.
- Zacks•21 days ago
Baxter (BAX) Beats on Q2 Earnings; Sales Meet Estimates
Baxter (BAX) gains from solid segmental performance in Q2.
- Zacks•21 days ago
Baxter International (BAX) Surpasses Q2 Earnings and Revenue Estimates
Baxter (BAX) delivered earnings and revenue surprises of 8.45% and 0.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•21 days ago
Baxter: 2Q Earnings Snapshot
The Deerfield, Illinois-based company said it had profit of 63 cents per share. Earnings, adjusted for non-recurring costs, came to 77 cents per share. The results beat Wall Street expectations. The average ...
- Business Wire•21 days ago
Baxter Reports Second-Quarter 2018 Results and Increases Earnings Outlook for Full-Year 2018
DEERFIELD, Ill.-- -- Second-quarter revenue of $2.8 billion increased 9 percent on a reported basis and 4 percent on an operational basis Second-quarter GAAP earnings per share of $0.63; Adjusted EPS of $0.77 increased 22 percent Company raises full-year 2018 GAAP EPS to $2.48 to $2.59; Adjusted EPS to $2.94 to $3.00 Baxter International Inc. , a leading global medical products company, today reported ...
Market Realist•22 days agoA Brief Overview of Zimmer Biomet’s Financials
In Q1 2018, Zimmer Biomet’s (ZBH) revenue grew ~2.3% YoY (year-over-year) to $2.0 billion. In constant currency, it fell 1.5% YoY.
Market Realist•22 days agoChecking In on Zimmer Biomet Stock
Yesterday, Zimmer Biomet (ZBH) stock closed at $114.61, ~10% higher than its 52-week low of $104.28 on April 6. The stock started rising on July 23 and hit a 52-week high of $129.95 the next day. Recent developments for the company, which are expected to boost its revenue growth, include the following: In June, Zimmer Biomet approved a quarterly cash dividend of $0.24 per share to be paid on July 31 to stockholders as of June 29. ...
- Zacks•22 days ago
Medical Product Earnings Lineup for Jul 26: BAX, EW & More
Streak of regulatory developments and deep R&D focus are likely to drive the Medical Product industry this earnings season. Here we take a quick look at four Medical Product majors that are going to release earnings results.
